PROGRAMME- 16TH SEPTEMBER 2024
Plenary 1: Building effective pharmaceutical policies for improving access to medicines.
Time: 13h00 to 14h30 SAST
Panelists | Institution | Presentation Title |
Department of Innovation and Emerging Technologies, WHO HQ, Geneva. Switzerland | Current Issues in terms of Pharmaceutical Policy | |
University of Huddersfield, United Kingdom/Editor of the Journal of Pharmaceutical Policy and Practice | Conceptual Framework to build pricing policies | |
World Health Organization Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Utrecht, The Netherlands | Methodological issues with pricing policy evaluations | |
Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada | Good governance of medicines: Moving toward independence, accountability, and transparency |
Questions and Discussions Break: 14h30 to 15h00
Abstract Session: Evidence Informed Policy
Time | Presenter | Institution | Presentation Title |
15h00 – 15h40 | A Rizvi, A Workentin | MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario. | 1. National essential medicine lists changes between 2017 and 2023: a descriptive study |
C Heredia | MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario. | 2. Differential global prioritization of access to molecularly identical medicines: cross-sectional study | |
M Zia Ul Haq | MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario. | 3. Rarely listed essential medicines in 158 nationals lists | |
F Malik | Independent consultant, Lahore, Pakistan and Global Accelerator for Paediatric Formulations Network (GAP- f), World Health Organization, Geneva, Switzerland. | 4. Pediatric formulations in national essential medicine lists: cross-sectional study | |
15h40-15h50 | T Moleman | World Health Organization Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Utrecht, The Netherlands | 5. Time to inclusion of medicines for diabetes, hepatitis C, HIV, oncology and tuberculosis on National Essential Medicines Lists compared to the WHO Model List |
15h50-16h00 | LM Molepo | United Nations Population Fund/ Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands | 6. Alignment of registration status, national essential medicines lists, and standard treatment guidelines of postpartum haemorrhage medicines in 16 in Southern African Development Community Countries |
16h00-16h30 | Chairs | Questions and Closing | |